PRFX logo

PainReform Ltd. Ordinary Shares


PRFX: PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.


Show PRFX Financials

Consumer Interest
SEC Filings

Recent trades of PRFX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by PRFX's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Depot formulations of a local anesthetic and methods for preparation thereof Feb. 19, 2019
  • Patent Title: Depot formulations of a hydrophobic active ingredient and methods for preparation thereof Dec. 26, 2017
  • Patent Title: Depot formulations of a local anesthetic and methods for preparation thereof Jun. 06, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of PRFX in WallStreetBets Daily Discussion


Recent insights relating to PRFX

CNBC Recommendations

Recent picks made for PRFX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in PRFX

Corporate Flights

Flights by private jets registered to PRFX